TENAX THERAPEUTICS INC(NASDAQ:TENX) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to TENX. TENX was compared to 562 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TENX as it has an excellent financial health rating, but there are worries on the profitability. TENX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TENX has reported negative net income.

TENX had a negative operating cash flow in the past year.

In the past 5 years TENX always reported negative net income.

In the past 5 years TENX always reported negative operating cash flow.

1.2 Ratios

TENX has a Return On Assets of -18.21%. This is in the better half of the industry: TENX outperforms 79.54% of its industry peers.

The Return On Equity of TENX (-19.13%) is better than 86.30% of its industry peers.

		Industry Rank	Sector Rank
ROA	-18.21%
ROE	-19.13%
ROIC	N/A

ROA(3y)-136.22%

ROA(5y)-220.51%

ROE(3y)-284.78%

ROE(5y)-368.86%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TENX has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, TENX has more shares outstanding

There is no outstanding debt for TENX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

TENX has an Altman-Z score of -1.07. This is a bad value and indicates that TENX is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of TENX (-1.07) is better than 60.50% of its industry peers.

TENX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.07

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 20.60 indicates that TENX has no problem at all paying its short term obligations.

TENX has a better Current ratio (20.60) than 94.84% of its industry peers.

A Quick Ratio of 20.60 indicates that TENX has no problem at all paying its short term obligations.

TENX has a Quick ratio of 20.60. This is amongst the best in the industry. TENX outperforms 94.84% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	20.6
Quick Ratio	20.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.96%, which is quite impressive.

EPS 1Y (TTM)84.96%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.61%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TENX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.87% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y83.51%

EPS Next 2Y34.71%

EPS Next 3Y22.69%

EPS Next 5Y16.87%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TENX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TENX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TENX's earnings are expected to grow with 22.69% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.71%

EPS Next 3Y22.69%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TENX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TENAX THERAPEUTICS INC

NASDAQ:TENX (5/14/2025, 10:43:47 AM)

5.75

+0.08 (+1.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2025-05-12

Earnings (Next)08-11 2025-08-11

Inst Owners61.26%

Inst Owner Change0%

Ins Owners0.28%

Ins Owner Change0%

Market Cap23.86M

Analysts88

Price Target22.44 (290.26%)

Short Float %7.45%

Short Ratio11.64

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)72.42%

Min EPS beat(2)58.23%

Max EPS beat(2)86.6%

EPS beat(4)3

Avg EPS beat(4)31.75%

Min EPS beat(4)-27.45%

Max EPS beat(4)86.6%

EPS beat(8)6

Avg EPS beat(8)24.36%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)6.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)71.43%

EPS NY rev (1m)74.52%

EPS NY rev (3m)68.18%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.26
P/tB	0.26
EV/EBITDA	N/A

EPS(TTM)-5.32

EYN/A

EPS(NY)-0.88

Fwd EYN/A

FCF(TTM)-3.57

FCFYN/A

OCF(TTM)-3.57

OCFYN/A

SpS0

BVpS22.17

TBVpS22.17

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-18.21%
ROE	-19.13%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-136.22%

ROA(5y)-220.51%

ROE(3y)-284.78%

ROE(5y)-368.86%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	20.6
Quick Ratio	20.6
Altman-Z	-1.07

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)84.96%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.61%

EPS Next Y83.51%

EPS Next 2Y34.71%

EPS Next 3Y22.69%

EPS Next 5Y16.87%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-136.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-36.04%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-150.88%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-150.88%

OCF growth 3YN/A

OCF growth 5YN/A

TENAX THERAPEUTICS INC (TENX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens